Latest news with #Rantac
Reuters
a day ago
- Business
- Reuters
Indian drugmaker JB Chem posts first-quarter profit jump on strong domestic demand
July 30 (Reuters) - Indian drugmaker JB Chemicals & Pharmaceuticals ( opens new tab reported an 8.9% higher first-quarter profit on Wednesday, led by healthy domestic demand for its drugs. The maker of "Rantac" antacid reported a consolidated net profit of 2.02 billion rupees ($23.02 million) for the quarter ended June 30, compared with 1.77 billion rupees a year earlier. Its overall revenue climbed 14.5% to 10.94 billion rupees, boosted by demand in its key domestic formulations business. The Indian pharmaceutical market grew 8% in June, led by drugs treating chronic conditions such as hypertension and diabetes, benefitting drugmakers specialising in such treatments. JB Chem's revenue from its chronic and acute portfolios surged 15% and 12%, respectively, while an 8% climb in its contract drug manufacturing business also aided its results. PEER COMPARISON * The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT APRIL TO JUNE STOCK PERFORMANCE -- All data from LSEG ($1 = 87.7400 Indian rupees)
News18
4 days ago
- Health
- News18
Ask Antacid Ranitidine Makers To Monitor Chances Of Cancer-Causing Impurity: Drug Controller To States
NDMA presence in the acid-reflux drug under scrutiny again; states told to ensure manufacturers take risk-based safety steps In a renewed move to safeguard public health, the Drugs Controller General of India (DCGI) has directed all state and union territory drug regulators to ensure that manufacturers of Ranitidine—a commonly used medicine for acidity—monitor levels of NDMA, a potential cancer-causing impurity, in their formulations. Ranitidine is a medication that lowers stomach acid production and helps relieve acid-related indigestion and heartburn. It is commonly available under brand names like Aciloc, Rantac, and Zinetac. The July 24 communication, seen by News18, follows the findings of a government-appointed expert committee and a subsequent meeting of the Drugs Technical Advisory Board (DTAB), the country's apex drug advisory body. The DTAB, in its 92nd meeting held on April 28, reviewed the expert panel's report on the NDMA contamination issue that has shadowed Ranitidine for several years. 'The issue related to safety of Ranitidine drug due to presence of NDMA impurity has been under consideration for quite some time and this office has taken various measures from time to time," the letter said. News18 first reported the recommendations of the expert panel on April 29. Critically, the DTAB advised that 'manufacturers should monitor the NDMA levels in the API/formulation and also take risk-based measures such as reducing the shelf life" of the product. Following this, the DCGI has asked state drug controllers to instruct Ranitidine manufacturers in their jurisdiction to initiate these monitoring and mitigation efforts immediately. '…as recommended by DTAB, you are requested to direct the manufacturers under your jurisdiction to monitor the NDMA levels in the API/formulation of Ranitidine and also take risk-based measures such as reducing the shelf life, etc." NDMA (N-nitroso dimethylamine) is classified as a probable human carcinogen. The impurity was first flagged globally in 2019, prompting recalls and regulatory reviews in several countries. In India, too, concerns around Ranitidine's safety have persisted, although the drug remains on the market. With the DTAB's latest push, the spotlight is once again on the need for proactive safety checks and strict quality surveillance by drugmakers, especially for older drugs that continue to see wide usage. view comments First Published: July 27, 2025, 07:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Indian Express
21-07-2025
- Indian Express
How Bombay HC flagged the ‘torture' of accused to ‘extort' confessional statements as key ground to deflate ATS case
Acquitting the 12 accused in the train blasts case, the Bombay High Court on Monday flagged the torture inflicted upon them to 'extort' their confessional statements and found it to be one of key reasons that discarded and vitiated prosecution's case. 'The accused succeeded in establishing the fact of torture inflicted on them to extort confessional statement,' the HC said. The HC said that confessional statements were 'not found truthful and complete on various grounds, including some portions of the same were found to be similar and copied.' The lawyers representing the accused including senior advocate S Murlidhar (former Delhi HC judge) had argued that the accused persons were languishing in jail for nearly 18 years based on confessional statements taken by the Maharashtra Anti-Terrorism Squad (ATS) through 'torture' in the form of beating, threatening and inducement and lost their prime years of lives in incarceration. The accused claimed that their torture was corroborated by medical evidence to 'very substantial degree,' which should render their confessions irrelevant in law under Section 24 of Indian Evidence Act. The HC observed that one of the accused, Mohammad Sajid Margub Ansari was 'fainting' while he was taken for medical examination on October 24, 2006 and he was advised Rantac tablet, ORS and glucose water. It is significant to note, the HC said that the report of the said date was before recording Part-1 of Ansari's confessional statement which mentioned that he was fainting while being examined. 'This remark speaks volume about the physical and mental condition of accused just before recording of Part-I of his confession. Therefore, the evidence discussed above casts serious doubt on the likelihood that torture was inflicted on accused to extort confession,' the court observed. It added that prosecution was 'not able to effectively refute' defence's allegations of torture and evidence of accused 'remained unshaken.' 'Thus, in view of language of Section 24 of Indian Evidence Act, we are of the opinion that the confessional statement of the accused is inadmissible in law,' the HC held. The court also perused medical evidence of doctors of KEM and Bhabha Hospital related to accused Mohamad Majid Mohamad Shafi and noted that it 'sufficiently hinted at the possibility of torture being inflicted on the accused to extort a confession.' The HC also referred to 'torture inflicted' on other accused while recording their confessional statements. The HC observed that before recording confessional statements, the authority has to ascertain whether any torture or inducement was done to the accused and should insist for medical examination and look into the medical reports. The bench refused to accept prosecution's argument that medical evidence of torture was available only for some and not all accused and same will not detract from strong suspicion that all confessions were obtained under torture. 'If so many accused have been tortured, the threat of torture will loom large for all the accused and be sufficient to vitiate their confession under Section 24 of the Indian Evidence Act,' the HC said. Justice Anil S Kilor, who authored 671-page judgment for the bench which also consisted of Justice Shyam C Chandak observed that one of the many grounds based on which confessional statements were rendered 'inadmissible' was that Part-I and II of some of the statements were 'identical.' The HC also said that variations in mentioning of offences in correspondences made by the concerned Deputy Commissioners of Police (DCPs) before or after recording a confession was also questionable. The court further emphasised on 'absence of certificates mandated under the MCOC Rules to establish voluntariness of confessions.' Moreover, it said that 'there was no relevant material available with the authority to reach a subjective satisfaction about the compliance of prerequisites for grant of prior approval' of designated authority, which was mandatory under MCOCA before recording the statements and the same suffered from 'non-application of mind.' The HC also noted that S K Jaiswal, who was then Deputy Inspector General (DIG), who granted prior approval, 'did not enter into the witness box to prove the contents of the letter of prior approval, and mere identification of Jaiswal's signature did not prove the approval and therefore, confession statements were 'inadmissible.'
Economic Times
30-06-2025
- Business
- Economic Times
Amnish Aggarwal on Torrent Pharma plan to acquire JB Chemicals, Jio Finance surge & IT and shipping stocks
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads , Head-Research,, says Torrent Pharma 's plans to acquire JB Chemicals will be an expensive deal. The acquisition will strengthen Torrent's branded generics in India and overseas. It will also help in CDMO space. The deal is expected to increase margins in the long term. Synergies will likely emerge by the second half of acquisition is at around six-and-a-half times EV to sales and it is definitely not cheap, that is one. Secondly, if you look at the portfolio of Torrent and the portfolio of JB Chemicals, whether it is medicines like Rantac, Nicardia or some of the other plays which JB Chemicals offers, in the domestic markets, it is definitely a complimentary deal and it offers them more branded generics in India and overseas and strengthens them in the CDMO need to pay out Rs 12,000 crore and do not have that kind of money in the balance sheet. Plus, it is slightly complicated because they are acquiring some stake and making an open offer and then the merger is there. In the longer term, there is a scope to increase margins. In the longer term, it will play out to the benefit of Torrent Pharma. But yes, in the near term, I do not think there is anything which is very meaningful on the table in terms of any immediate traction to the stock the longer term, definitely, Torrent Pharma will gain from it, may not be in FIY26, because the debt will come on the balance sheet, but as you said, by FY27 second half, by when they want to get rid of the debt, the synergies will also start coming in and might push their margins up by 2% to 3%. So, in the longer term, it will add value to Torrent is very difficult to say because it is a very volatile stock. Earlier from close to Rs 200-220, it went all the way to Rs 340-350. In terms of business, there are not many material things happening. They are gradually building up and might be looking at mutual funds. Then they are looking at lending. But on a very fundamental basis, I would not be able to give any reasons why the stock price has shown an upward IT services, the commentaries are not likely to be very different from what we have seen in the past couple of quarters. There might be solitary cases here or there where they might give some indication of recovery. But what we are learning as of now is that there is no big change in commentary. In the near to medium term, at least for the next couple of quarters, we will not see any meaningful uptake it will depend upon various segments. Some of the companies in BFSI or AI-related, might see some sort of stability, but for ER&D and companies which are catering to auto related stuff in Europe, we will continue to see pressure building up. There is no big change there. Some of the niches will continue to do well, but in terms of commentary, we are not expecting anything drastic as far as IT services are acquisition is a positive because for Indian companies which are on the shipping side, whether commercial or defence, first of all, there is a huge runway of growth as we are not building enough ships – be it commercial ships or those for defence is also positive for a company like say Mazagon Dock which is into submarines and all sorts of ships. As far as the Sri Lankan acquisition is concerned, it will be primarily for the commercial wing because it would not be possible to extend the defence wing over all these shipping companies could be looking at expanding their production, particularly the commercial ship building side because India hardly makes anything and that too above the 10,000 DWT weight. I am not sure as of now if that particular shipyard has the capacity to build larger ships of more than 10,000 DWT or 20,000 DWT but if that happens, it will give Mazagon Dock a lot of fuel to accelerate growth because India wants to develop its ship building industry in a big it remains quite an expensive stock. It has run up quite sharply after the brief reaction which happened towards the Q3 of last year and from here on, in all these names, one will have to take a very long-term viewpoint of three to five years at least to make any very sizable returns.
Time of India
30-06-2025
- Business
- Time of India
Amnish Aggarwal on Torrent Pharma plan to acquire JB Chemicals, Jio Finance surge & IT and shipping stocks
Live Events You Might Also Like: Rakshit Ranjan on sectors to focus on to geopolitically risk-proof your portfolio You Might Also Like: Torrent Pharma shares surge 4% after agreeing to acquire JB Chemicals for Rs 11,900 crore (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel , Head-Research,, says Torrent Pharma 's plans to acquire JB Chemicals will be an expensive deal. The acquisition will strengthen Torrent's branded generics in India and overseas. It will also help in CDMO space. The deal is expected to increase margins in the long term. Synergies will likely emerge by the second half of acquisition is at around six-and-a-half times EV to sales and it is definitely not cheap, that is one. Secondly, if you look at the portfolio of Torrent and the portfolio of JB Chemicals, whether it is medicines like Rantac, Nicardia or some of the other plays which JB Chemicals offers, in the domestic markets, it is definitely a complimentary deal and it offers them more branded generics in India and overseas and strengthens them in the CDMO need to pay out Rs 12,000 crore and do not have that kind of money in the balance sheet. Plus, it is slightly complicated because they are acquiring some stake and making an open offer and then the merger is there. In the longer term, there is a scope to increase margins. In the longer term, it will play out to the benefit of Torrent Pharma. But yes, in the near term, I do not think there is anything which is very meaningful on the table in terms of any immediate traction to the stock the longer term, definitely, Torrent Pharma will gain from it, may not be in FIY26, because the debt will come on the balance sheet, but as you said, by FY27 second half, by when they want to get rid of the debt, the synergies will also start coming in and might push their margins up by 2% to 3%. So, in the longer term, it will add value to Torrent is very difficult to say because it is a very volatile stock. Earlier from close to Rs 200-220, it went all the way to Rs 340-350. In terms of business, there are not many material things happening. They are gradually building up and might be looking at mutual funds. Then they are looking at lending. But on a very fundamental basis, I would not be able to give any reasons why the stock price has shown an upward IT services, the commentaries are not likely to be very different from what we have seen in the past couple of quarters. There might be solitary cases here or there where they might give some indication of recovery. But what we are learning as of now is that there is no big change in commentary. In the near to medium term, at least for the next couple of quarters, we will not see any meaningful uptake it will depend upon various segments. Some of the companies in BFSI or AI-related, might see some sort of stability, but for ER&D and companies which are catering to auto related stuff in Europe, we will continue to see pressure building up. There is no big change there. Some of the niches will continue to do well, but in terms of commentary, we are not expecting anything drastic as far as IT services are acquisition is a positive because for Indian companies which are on the shipping side, whether commercial or defence, first of all, there is a huge runway of growth as we are not building enough ships – be it commercial ships or those for defence is also positive for a company like say Mazagon Dock which is into submarines and all sorts of ships. As far as the Sri Lankan acquisition is concerned, it will be primarily for the commercial wing because it would not be possible to extend the defence wing over all these shipping companies could be looking at expanding their production, particularly the commercial ship building side because India hardly makes anything and that too above the 10,000 DWT weight. I am not sure as of now if that particular shipyard has the capacity to build larger ships of more than 10,000 DWT or 20,000 DWT but if that happens, it will give Mazagon Dock a lot of fuel to accelerate growth because India wants to develop its ship building industry in a big it remains quite an expensive stock. It has run up quite sharply after the brief reaction which happened towards the Q3 of last year and from here on, in all these names, one will have to take a very long-term viewpoint of three to five years at least to make any very sizable returns.
